Table of Contents

• You might want to know


• Main Topic


• Key Insights Table


• Afterwards...

You might want to know

1. What prompted the recall of Tavneos (Avacopan) and how immediate is the action in Ireland?

2. What should patients currently taking the medicine do, and how are regulators across Europe responding?

Main Topic

Tavneos (generic name: Avacopan) is a targeted therapy developed to treat adults with certain severe and rare autoimmune conditions that cause inflammation of blood vessels, known as ANCA-associated vasculitis. The medicine, produced by US-based Amgen and distributed globally through licensing agreements with other pharmaceutical companies, has been the subject of safety reviews and regulatory scrutiny following reports from post-marketing surveillance.

In recent months, concerns have risen after company reports from a license holder in Japan indicated fatalities among patients treated with Tavneos. Specifically, Kissei — the company holding rights in Japan — reported approximately 20 deaths among more than 8,500 treated patients since 2022. These figures prompted further investigation, although both Kissei and Amgen have cautioned that the available case reports do not establish a definitive causal relationship between the drug and those deaths. Amgen noted that some reported cases could not be conclusively linked to the product.

Regulatory bodies across Europe and the UK undertook independent assessments of the available safety data. The European Medicines Agency (EMA) conducted a review and subsequently recommended that the marketing authorization for Tavneos be withdrawn. This recommendation was endorsed by the European Commission, which serves as the formal decision-making authority on centralized EU marketing authorizations. Following that endorsement, national regulators implemented measures to remove the product from their markets.

In the Republic of Ireland, the Health Products Regulatory Authority (HPRA) directed wholesalers to halt distribution of Tavneos on 11 August. The HPRA then requested the recall of any remaining wholesaler stock. Irish reporting indicated that prior to the EMA recommendation, Tavneos had been used in roughly 60 patients in the country. The HPRA stressed that prescribing had been limited to consultants with specialist expertise in these rare conditions and that some clinicians had proactively discontinued treatment for certain patients.

Regulators have emphasized patient safety while also cautioning against abrupt cessation of therapy without clinical advice. The HPRA specifically advised that patients currently receiving Tavneos should not stop treatment without first consulting their treating physician, because sudden discontinuation of therapy for active vasculitis may carry substantial health risks. Specialist clinicians are therefore responsible for evaluating each patient’s treatment plan, weighing potential risks and benefits, and arranging suitable alternative management where necessary.

National measures mirrored EU-level actions: France’s ANSM announced a recall of all available batches beginning on 19 August. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) initiated its own review earlier in the summer and stated in June that it was assessing the benefit–risk profile, promising to communicate the outcome and any changes to licensing status in due course. These steps reflect a coordinated regulatory response focused on collecting and evaluating data before making final determinations on long-term availability.

It is important to note the distinction between an immediate, precautionary market withdrawal and an established causal finding. The EMA’s recommendation to revoke the marketing authorization indicates that regulators found the totality of available evidence sufficient to remove the product pending further clarity. However, the data reported to date include cases where a causal link between Tavneos and adverse outcomes could not be determined. Ongoing pharmacovigilance, case-level reviews, and possible additional studies are necessary to clarify the nature and magnitude of any risk associated with the medication.

From a clinical and public-health perspective, the situation underscores several points: first, even after clinical trial approval and market authorization, rare adverse events may only become apparent during widespread use; second, international pharmacovigilance systems and inter-agency communication play a critical role in timely identification of safety signals; third, decisions to recall or suspend a medicine balance uncertain risks against the therapeutic needs of patients with few alternative options.

Stakeholders affected by the withdrawal include patients currently on therapy, specialist prescribers, hospital pharmacies, wholesalers, and national health systems that manage rare-disease care pathways. Practical steps underway or advised by regulators typically include recalling distributed stock, notifying clinicians and patients, advising on clinical management and monitoring, and collecting further safety data. Where appropriate, regulators may also request that manufacturers conduct additional analyses, provide access to case reports, or implement risk-minimization measures.

For patients and clinicians, the immediate priorities are individualized clinical assessments and clear communication. Clinicians should review treatment indications, monitor for signs or symptoms suggestive of drug-related adverse effects, and discuss alternative therapeutic strategies where indicated. Patients should be supported to understand why the regulatory action has been taken and the importance of not interrupting therapy without medical guidance.

In summary, Tavneos (Avacopan) has been the focus of a precautionary withdrawal from the Irish market after European authorities recommended revoking its marketing authorization amid reported fatalities in post-marketing surveillance. While causal relationships remain under evaluation, regulators have acted to remove the drug from distribution and to recall available stock, while advising patients to consult their healthcare providers before making any treatment changes. The coordinated regulatory response reflects a commitment to patient safety while further evidence is gathered.

Key Insights Table

Afterwards...

Looking forward, regulators and manufacturers will continue investigating the reported cases to determine whether a causal relationship exists and whether further regulatory measures are required. Additional pharmacovigilance data, independent case reviews, and potentially new safety studies may clarify risks. Clinicians should remain vigilant, report suspected adverse reactions through national reporting systems, and discuss treatment options and monitoring plans with affected patients. Patients should expect outreach from their care teams and be supported through treatment transitions if alternative therapies are recommended.

The Tavneos case highlights the dynamic nature of drug safety oversight and the importance of transparent, evidence-based decision-making when rare but serious events emerge after approval. Coordination among international regulators, manufacturers, healthcare professionals, and patient communities will be essential to resolve outstanding questions while minimizing harm to patients who rely on effective therapies for life‑threatening conditions.